Literature DB >> 18800869

Long-term IOP lowering with bimatoprost in open-angle glaucoma patients poorly responsive to latanoprost.

Sriram Sonty1, Vikrant Donthamsetti, Gautam Vangipuram, Afzal Ahmad.   

Abstract

PURPOSE: The aim of this study was to study long-term intraocular pressure (IOP) lowering following a switch to bimatoprost in patients with open-angle glaucoma (OAG) not at target IOP while on latanoprost either as monotherapy or as polytherapy with other topical adjunctive agents.
METHODS: A retrospective review of OAG patients, with <20% IOP lowering from pretreatment baseline while on latanoprost either as monotherapy or in combination with adjunctive agents who were switched to bimatoprost, was conducted. Main outcome measures were mean IOP at 6, 12, and 24 months following the switch to bimatoprost and percent IOP lowering from baseline IOP before the switch.
RESULTS: Records of 30 patients (30 right eyes [OD], 29 left eyes [OS]) were reviewed. Mean IOP preswitch was 23.1 +/- 4.3 mmHg in OD and 22.3 +/- 3.8 mmHg in OS. Postswitch to bimatoprost, IOP was significantly reduced (P < 0.005) at each of the time points studied and patients experienced additional IOP lowering ranging from 17.8 to 22.0% in OD and 15.0-24.0% in OS. Bimatoprost was well tolerated in all but 1 patient.
CONCLUSIONS: Significant additional long-term IOP lowering may be achieved by switching to bimatoprost in patients with open-angle glaucoma who are not at target IOP with latanoprost.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18800869     DOI: 10.1089/jop.2008.0033

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  6 in total

1.  Efficacy and safety of bimatoprost in glaucoma and ocular hypertension in non-responder patients.

Authors:  Nicholas Brennan; Mohammad H Dehabadi; Sandhya Nair; Ana Quartilho; Catey Bunce; Ian Reekie; Raal Obikpo
Journal:  Int J Ophthalmol       Date:  2017-08-18       Impact factor: 1.779

2.  Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys.

Authors:  B'Ann True Gabelt; Elizabeth A Hennes; Mark A Bendel; Chase E Constant; Mehmet Okka; Paul L Kaufman
Journal:  J Ocul Pharmacol Ther       Date:  2009-02       Impact factor: 2.671

3.  Bimatoprost effects on aqueous humor dynamics in monkeys.

Authors:  David F Woodward; Achim H-P Krauss; Siv F E Nilsson
Journal:  J Ophthalmol       Date:  2010-05-23       Impact factor: 1.909

4.  Switching efficacy on intraocular pressure from latanoprost to bimatoprost in eyes with open angle glaucoma: implication to the changes of central corneal thickness.

Authors:  Akira Sawada; Tetsuya Yamamoto
Journal:  Jpn J Ophthalmol       Date:  2014-07-09       Impact factor: 2.447

5.  Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China.

Authors:  Kaidi Wang; Li Xu; Zhilan Yuan; Ke Yao; Junmei Zhao; Liang Xu; Aiwu Fang; Mingzhi Zhang; Lingling Wu; Jian Ji; Jiamin Hou; Qing Liu; Xinghuai Sun
Journal:  BMC Ophthalmol       Date:  2014-02-25       Impact factor: 2.209

6.  Evaluating intraocular pressure-lowering solutions for the treatment of open-angle glaucoma: comparison between bimatoprost 0.03% and bimatoprost 0.01% - an observational switch study.

Authors:  Sarita S Deshpande; Sriram Sonty; Afzal Ahmad
Journal:  Clin Ophthalmol       Date:  2017-07-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.